Prelude Therapeutics Incorporated
NASDAQ:PRLD
Overview | Financials
| Company Name | Prelude Therapeutics Incorporated |
| Symbol | PRLD |
| Currency | USD |
| Price | 1.25 |
| Market Cap | 68,980,434 |
| Dividend Yield | 0% |
| 52-week-range | 0.61 - 5.53 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Krishna Vaddi D.V.M., Ph.D. |
| Website | https://www.preludetx.com |
An error occurred while fetching data.
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD









